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Background: Previous studies indicate increased prevalences of suicidal ideation, suicide attempts, and
completed suicide in Huntington's disease (HD) compared with the general population. This study
investigates correlates and predictors of suicidal ideation in HD.
Methods: The study cohort consisted of 2106 HD mutation carriers, all participating in the REGISTRY
study of the European Huntington's Disease Network. Of the 1937 participants without suicidal ideation
at baseline, 945 had one or more follow-up measurements. Participants were assessed for suicidal
ideation by the behavioural subscale of the Uniﬁed Huntington's Disease Rating Scale (UHDRS).
Correlates of suicidal ideation were analyzed using logistic regression analysis and predictors were
analyzed using Cox regression analysis.
Results: At baseline, 169 (8.0%) mutation carriers endorsed suicidal ideation. Disease duration (odds ratio
[OR]¼0.96; 95% conﬁdence interval [CI]: 0.9–1.0), anxiety (OR¼2.14; 95%CI: 1.4–3.3), aggression
(OR¼2.41; 95%CI: 1.5–3.8), a previous suicide attempt (OR¼3.95; 95%CI: 2.4–6.6), and a depressed
mood (OR¼13.71; 95%CI: 6.7–28.0) were independently correlated to suicidal ideation at baseline. The
4-year cumulative incidence of suicidal ideation was 9.9%. Longitudinally, the presence of a depressed
mood (hazard ratio [HR]¼2.05; 95%CI: 1.1–4.0) and use of benzodiazepines (HR¼2.44; 95%CI: 1.2–5.0) at
baseline were independent predictors of incident suicidal ideation, whereas a previous suicide attempt
was not predictive.
Limitations: As suicidal ideation was assessed by only one item, and participants were a selection of all
HD mutation carriers, the prevalence of suicidal ideation was likely underestimated.
Conclusions: Suicidal ideation in HD frequently occurs. Assessment of suicidal ideation is a priority in
mutation carriers with a depressed mood and in those using benzodiazepines.
& 2013 Elsevier B.V. All rights reserved.1. Introduction
Huntington's disease (HD) is an autosomal dominant progres-
sive neurodegenerative disease (Walker, 2007). The underlying
genetic defect is an unstable and expanded CAG repeat on the
short arm of chromosome 4, which causes an expanded poly-
glutamine chain in the huntingtin protein (Hoogeveen et al., 1993).
The disease is characterized by motor abnormalities, cognitivell rights reserved.
ter Department of Psychiatry,
lands. Tel.: +31 71 5263785;
ers).decline, and both behavioural problems and psychiatric disorders.
George Huntington ﬁrst described the tendency to suicide as an
important aspect of the disease in 1872 (Huntington, 1872). Recent
studies have reported that completed suicide rates among HD
mutation carriers are four to eight times higher compared with the
general population (Farrer, 1986; Robins Wahlin et al., 2000;
Schoenfeld et al., 1984), and increased prevalences of suicidal
ideation and attempted suicide, of up to 20%, have been reported
(Hubers et al., 2012; Wetzel et al., 2011).
Previous cross-sectional studies have shown that both socio-
demographic characteristics such as having no offspring (Baliko
et al., 2004; Lipe et al., 1993) or being unemployed (Almqvist et al.,
1999), and clinical characteristics such as the presence of a
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aggression (Wetzel et al., 2011), or having a psychiatric history
(Almqvist et al., 1999) are associated with suicidal ideation,
suicide attempts, or completed suicide in HD. Some of these
studies only included a small number of participants (Lipe et al.,
1993) or used data obtained from family members (Di Maio et al.,
1993). Also, several of these studies only investigated the effect
of undergoing genetic testing on suicide risk (Almqvist et al.,
1999; Farrer, 1986; Robins Wahlin et al., 2000), without investi-
gating correlates or predictors of suicidal ideation during disease
progression.
Despite the high suicide risk in HD, only two prospective
studies have been carried out (Fiedorowicz et al., 2011; Hubers
et al., 2012). One study investigating both suicide attempts and
completed suicide in 735 prodromal HD mutation carriers during a
median follow-up of 3.5 years, reported presence of depression
and a history of suicide attempts as relevant predictors
(Fiedorowicz et al., 2011). However, there were only 13 incident
events, which limited study power (Fiedorowicz et al., 2011). The
other longitudinal study, in which 100 mutation carriers were
assessed for both suicidal ideation and suicide attempts, reported
7 participants who developed suicidal ideation or attempted
suicide after two years follow-up. This study also found depressed
mood as a predictor for suicidal ideation and attempts in HD
(Hubers et al., 2012).
The present study aimed to identify correlates and predictors of
suicidal ideation in a large well-monitored European cohort of HD
mutation carriers.Mutation carriers
assessed for suicidal ideation
n = 2,106
 992 (51.2%) no follow-up (drop-out)*
Suicidal ideation at baseline
No suicidal ideation
n = 1,937 (92.0%)
Suicidal ideation
n = 169 (8.0%)
Suicidal ideation at follow-up
Mutation carriers
n = 945
No suicidal ideation
n = 893
Suicidal ideation
n = 52
Fig. 1. Flowchart of drops-outs. * drop-outs had a signiﬁcantly longer estimated
duration of disease, lower Total Functioning Capacity (TFC) score and higher
Uniﬁed Huntington's Disease Rating Scale (UHDRS)-motor score. No signiﬁcant
difference in any of the neuropsychiatric characteristics.2. Method
2.1. Participants
The study cohort consisted of 2106 European HD mutation
carriers participating in the REGISTRY study prior to February
2011. Our study included only monitored data of REGISTRY
participants who had a Uniﬁed Huntington's Disease Rating Scale
(UHDRS) (Huntington Study Group, 1996) behavioural assessment.
REGISTRY is a large prospective, observational study of the
European Huntington's Disease Network (EHDN) describing the
natural course of HD in many European countries (Orth et al.,
2010). More detailed information can be found at http://www.
euro-hd.net/html/registry.
In the study cohort, participants from 15 European countries
were included: Austria (n¼58), Belgium (n¼3), Czech Republic
(n¼29), Finland (n¼23), France (n¼158), Germany (n¼493), Italy
(n¼181), The Netherlands (n¼215), Norway (n¼74), Poland
(n¼222), Portugal (n¼65), Spain (n¼160), Sweden (n¼18),
Switzerland (n¼21) and the United Kingdom (n¼386). Full ethical
approval for REGISTRY was obtained in each of the participating
countries and all participants gave written informed consent after
the study procedure had been fully explained. The ﬁrst beha-
vioural assessment according to the behavioural subscale of the
Uniﬁed Huntington's Disease Rating Scale (UHDRS-b) (Huntington
Study Group, 1996) was taken as baseline visit. Follow-up data
from mutation carriers free of suicidal ideation at baseline
(n¼1,937) were used in the longitudinal analyses. Of these
mutation carriers, 992 participants dropped out because they
had no follow-up measurements. This resulted in 945 eligible
mutation carriers for follow-up assessment (Fig. 1).
2.2. Instruments
Assessment of suicidal ideation: Suicidal ideation was examined
using the UHDRS-b (Huntington Study Group, 1996). Thebehavioural subscale of the UHDRS assesses frequency and sever-
ity of 11 neuropsychiatric symptoms (Huntington Study Group,
1996). The item ‘Suicidal thoughts' of the UHDRS-b (Huntington
Study Group, 1996) measures frequency and severity of suicidal
thoughts in the month preceding the interview. The frequency
score ranges from 0 through 4: a score of 0 indicates suicidal
thoughts are never present, a score of 1 indicates seldom presence,
a score of 2 indicates suicidal thoughts are sometimes present, a
score of 3 indicates frequent presence, and a score of 4 indicates
suicidal thoughts are often present. The severity score also ranges
from 0 through 4: a score of 0 indicates absence of suicidal
ideation, a score of 1 indicates there are no current suicidal
thoughts, but the participant considers suicide as a potential
option, a score of 2 indicates presence of ﬂeeting suicidal ideation,
a score of 3 indicates the participant seriously considered suicide
but has no plan, and a severity score of 4 indicates the participant
has a plan and is actively preparing (Huntington Study Group,
1996). The total score was computed by multiplying the frequency
and severity scores (range 0–16 points) (Wetzel et al., 2011). Based
on clinical experience, a total score 41 point on this item was
used to characterize presence of suicidal ideation, meaning that
participants scoring a total score of 1 on the ‘suicidal ideation’ item
were not considered to have suicidal ideation, since suicidal
ideation is then ‘not currently and seldom’ present according to
the participant or interviewer. When participants had ﬂeeting
suicidal thoughts, although ‘seldom’ (less than once per month),
they scored 2 points on the ‘suicidal ideation’ item, and were
considered to have suicidal ideation. This cut-off value also implies
that participants that consider suicide as a potential option for the
future, and ‘seldom’ think about this, were not considered to have
suicidal ideation.
Assessment of neuropsychiatric characteristics: The presence of
depressed mood, anxiety, apathy, irritability, and aggression was also
assessed with the UHDRS-b (Huntington Study Group, 1996). Total
scores for these separate items were computed by multiplying their
severity (range 0–4 points) and frequency (range 0–4 points) scores.
Based on clinical experience, a total score 41 point on such an item
Table 1
Correlates of suicidal ideation in Huntington's disease mutation carriers at baseline.
HD mutation carriers
without suicidal
ideation (n¼1937)
HD mutation carriers
with suicidal
ideation (n¼169)
P-valuea
Sociodemographic
characteristics
Male gender 994 (51.3%) 78 (46.2%) 0.20
Age (years) 50.5712.4 48.7711.3 0.08
Clinical
characteristics
CAG repeats
(number)
44.674.4 44.474.2 0.59
Estimated
duration of
disease (years)
5.978.1 3.778.0 0.001
TFC score 8.0 (5–12) 8.0 (6–11) 0.73
UHDRS-motor
score
35.3719.7 33.1720.4 0.18
Pre-motor
symptomatic
38 (2.0%) 6 (3.6%) 0.16
Psychotropic
medication
Any psychotropic
medication
1080 (59.0%) 109 (68.1%) 0.03
Antidepressant
use
660 (35.6%) 80 (50.0%) o0.001
Antipsychotic use 645 (34.5%) 64 (38.8%) 0.27
Benzodiazepine
use
303 (16.2%) 45 (29.0%) o0.001
Mood stabilizer/
anti-epileptic
use
132 (6.9%) 19 (11.4%) 0.03
Tetrabenazine use 96 (5.0%) 10 (6.0%) 0.59
Neuropsychiatric
characteristics
Depressed mood 771 (39.8%) 159 (94.1%) o0.001
Anxiety 641 (33.1%) 114 (67.5%) o0.001
Apathy 881 (45.7%) 123 (73.7%) o0.001
Irritability 775 (40.4%) 105 (63.3%) o0.001
Aggression 395 (20.5%) 79 (47.0%) o0.001
Suicide attempt in
past
123 (6.4%) 45 (26.6%) o0.001
Data are presented as n (%), mean (7SD) or median (interquartile range [IQR])
when appropriate. HD denotes Huntington's disease; TFC, total functional capacity;
UHDRS, uniﬁed Huntington's disease rating scale. 117 missing values for use of
psychotropic medication; 91 missing values for antidepressant use; 72 missing
values for antipsychotic use; 81 missing values for benzodiazepine use; 21 missing
values for mood stabilizer/anti-epileptic use; 33 missing values for tetrabenazine
use; 1 missing value for presence of anxiety; 12 missing values for presence of
apathy; 21 missing values for presence of irritability; 12 missing values for
presence of aggression.
a P-values by chi-square tests for categorical data, by unpaired t-tests for
independent samples with normal distribution, or non-parametric Mann–Whitney
U test for continuous variables without normal distributions.
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characteristic.
Assessment of sociodemographic and clinical characteristics: Data
on sociodemographic and clinical characteristics were collected
using detailed electronic case report forms. Participants were
examined by clinicians with longstanding experience in HD
(Orth et al., 2011).
The estimated disease duration was calculated by the current
age minus the estimated age of onset, calculated using the formula
of Vassos et al. (2008).
Global functioning was assessed with the Total Functioning
Capacity (TFC) (Huntington Study Group, 1996) with scores ran-
ging from 0 through 13 points. Higher scores indicate better global
functioning (Shoulson and Fahn, 1979). Disease stage was derived
from TFC scores (Shoulson, 1981).
A trained neurologist assessed motor functioning according to
the motor subscale of the UHDRS (UHDRS-m) (Huntington Study
Group, 1996) with scores ranging from 0 through 124 points.
Higher scores indicate worse motor functioning (Huntington Study
Group, 1996). Mutation carriers were considered motor sympto-
matic if the total score on the UHDRS-m was 44 points.
Medication use at baseline was determined based on the pro-
vided start and stop dates. If medication use at baseline could not be
unequivocally determined, this variable was considered missing.
2.3. Statistical analyses
Data are presented as n (%), mean (7SD), or median (inter-
quartile range [IQR]) when appropriate. Characteristics of muta-
tion carriers with and without suicidal ideation were compared by
chi-squared tests for categorical data, two-tailed t-tests for inde-
pendent samples with normal distribution, or non-parametric
Whitney-U tests.
The signiﬁcant univariate cross-sectional correlates were
included in a multivariate logistic regression analysis, while
forcing sex, age, and country in the model, to yield independent
correlates of suicidal ideation. The overall use of psychotropic
medication was not included in the multivariate analysis because
of overlap with use of the different component kinds of
psychotropics.
Mutation carriers free of suicidal ideation at baseline were
followed-up until they developed suicidal ideation (incident
cases). If participants did not develop suicidal ideation within four
years from baseline, they were censored. Incident cases were
compared with mutation carriers who did not develop suicidal
ideation using univariate Cox regression analysis. The signiﬁcant
univariate longitudinal predictors were included in a multivariate
Cox regression analysis, while forcing sex, age, and country in the
model, to yield the independent predictors of suicidal ideation.
Additional sensitivity analyses were conducted in which missing
data were imputed by either 0 or 1. Furthermore, a sensitivity
analysis using only a severity score of the UHDRS suicidal ideation
item 41 point to classify participants as having suicidal ideation
was carried out. In this way, participants who had no current
suicidal thoughts and only considered suicide as a potential option
for the future were no longer classiﬁed as having suicidal ideation,
while all participants with current suicidal ideation were, irre-
spective of the frequency of those thoughts.
A P-value o0.05 was considered statistically signiﬁcant. SPSS
version 20.0 was used.3. Results
The 2106 participants were both male (50.9%) and female
(49.1%) with a mean (7SD) age of 50.3 (712.4) years. The studypopulation included mostly motor symptomatic (98%) mutation
carriers. The mean (7SD) estimated disease duration was 5.7
(78.1) years. The study cohort consisted of mutation carriers from
all TFC stages: stage 1: n¼701 (33.3%), stage 2: n¼694 (33.0%),
stage 3: n¼537 (25.5%), stage 4: n¼148 (7.0%), stage 5: n¼26
(1.2%). Psychotropics were used by 1189 (56.5%) mutation carriers:
740 (35.1%) participants used antidepressants, 709 (33.7%) anti-
psychotics, 348 (16.5%) benzodiazepines, and 151 (7.2%) mood
stabilizers/anti-epileptics (data not shown). At baseline, 169 (8.0%)
mutation carriers endorsed suicidal ideation, whereas 1937
(92.0%) did not (Fig. 1). The prevalences of suicidal ideation in
the three largest participating countries were 6.9% in Germany,
7.5% in the United Kingdom, and 10.4% in Poland (data not shown).
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Mutation carriers with suicidal ideation at baseline had a
signiﬁcantly shorter estimated disease duration and a signiﬁcantly
higher use of psychotropics (speciﬁcally antidepressants, benzo-
diazepines, and mood stabilizers/anti-epileptics) compared with
mutation carriers without suicidal ideation. Furthermore, the
baseline presence of a depressed mood, anxiety, apathy, irritability,
aggression, and also the presence of a suicide attempt in the past
were all signiﬁcantly correlated with suicidal ideation (Table 1).
Using multivariate analyses, the estimated disease duration
(odds ratio [OR]¼0.96; 95% conﬁdence interval [CI]: 0.93–0.99),
presence of depressed mood (OR¼13.71; 95% CI: 6.71–28.00),
anxiety (OR¼2.14; 95% CI: 1.40–3.26), aggression (OR¼2.41; 95%
CI: 1.53–3.80), and previous suicide attempt (OR¼3.95; 95% CI:
2.36–6.60) were signiﬁcant independent correlates of suicidal
ideation (Table 2). As 190 cases were excluded from the multi-
variate analysis due to missing data, two additional sensitivity
analyses were conducted in which missing data were imputed by
either 0 or 1. Both of these sensitivity analyses yielded similar
results, with comparable odds ratios for all correlates (data not
shown).
To see whether correlates of suicidal ideation remained the
same when only using the severity score of the ‘suicidal ideation’
item of the UHDRS-b, we carried out a multinomial regression
analysis, comparing mutation carriers with a severity score of 0 on
the suicidal ideation item to mutation carriers with a severity
score of 1 and to mutation carriers with a severity score 41. This
sensitivity analysis conﬁrmed most of the previous results, with
higher or comparable odds ratios in the group mutation carriers
with a severity score 41 for all neuropsychiatric correlates and
increasing odds ratios as the severity score rose. Only the esti-
mated disease duration became a weaker correlate (data not
shown).3.2. Suicidal ideation at follow-up
Of the 1937 mutation carriers free of suicidal ideation at baseline,
945 were followed up for a median (IQR) period of 2.0 (1.1–3.0) years.Table 2
Independent correlates of suicidal ideation in Huntington's disease mutation carriers at
Cross-sectional logi
No suicidal ideation at baseline (n¼17
Baseline variable Reference
Sociodemographic and clinical characteristics
Male gender 1.00
Age 1.00
Estimated duration of disease 1.00
Psychotropic medication
Antidepressant use 1.00
Benzodiazepine use 1.00
Mood stabilizers/anti-epileptic use 1.00
Neuropsychiatric characteristics
Depressed mood 1.00
Anxiety 1.00
Apathy 1.00
Irritability 1.00
Aggression 1.00
Suicide attempt in past 1.00
Covariates cross-sectional analysis (enter model): all variables with P-value ≤0.05 in the uni
use of benzodiazepines, use of mood stabilizers/anti-epileptics, presence of depressed
aggression, and suicide attempt in the past) and sex, age, and country were forced into
a 190 cases excluded due to missing values.
b Odds ratio, 95% conﬁdence interval (CI), Wald statistic, degrees of freedom (df), anThe 992 drop-outs, had a signiﬁcantly longer estimated disease
duration (p¼0.040), lower TFC score (po0.001), and higher UHDRS-
m score (po0.001). When comparing neuropsychiatric characteristics,
the drop-outs did not differ signiﬁcantly from the participants that
were included in the follow-up analyses (data not shown).
After four years of follow-up 9.9% of the mutation carriers had
developed suicidal thoughts. These mutation carriers had signiﬁ-
cantly higher hazard ratios for the use of benzodiazepines and
mood stabilizers/anti-epileptics at baseline. Also, they had signiﬁ-
cantly higher hazard ratios for the presence of a depressed mood,
anxiety, and apathy at baseline (Table 3).
Using multivariate Cox regression analysis, the use of benzo-
diazepines at baseline (hazard ratio [HR]¼2.44; 95% CI: 1.20–4.97)
and the presence of a depressed mood (HR¼2.05; 95% CI: 1.06–
3.96) at baseline were independent predictors of suicidal ideation
at follow-up (Table 4) (Fig. 2). As 57 cases were excluded from the
multivariate Cox regression analysis due to missing data, again
two additional sensitivity analyses were conducted imputing
either 0 or 1 for the missing data. These sensitivity analyses
conﬁrmed our results, with comparable hazard ratios for all
predictors (data not shown).
To see whether predictors of suicidal ideation remained the
same when only using the severity score of the ‘suicidal ideation’
item of the UHDRS-b, we carried out a multivariate Cox regression
analysis comparing mutation carriers with a severity score o1 on
the suicidal ideation item to mutation carriers with a severity
score 41. This sensitivity analysis mostly conﬁrmed previous
results, with a comparable hazard ratio for the predictor depressed
mood. Although the hazard ratio for benzodiazepine use
decreased, it remained 42 (data not shown).4. Discussion
The results of this study demonstrate that mutation carriers
with suicidal ideation at baseline, more often had a depressed
mood, were more often anxious and aggressive, more often
attempted suicide in the past, and had a shorter estimated disease
duration compared with mutation carriers free of suicidal ideation.baseline.
stic regression (n¼1916)a
72) Suicidal ideation at baseline (n¼144)
Odds ratio (95% CI)b Wald statisticb df¼1 P-valueb
1.16 (0.79–1.71) 0.56 0.46
1.02 (0.99–1.04) 2.12 0.15
0.96 (0.93–0.99) 6.27 0.01
0.93 (0.62–1.40) 0.12 0.73
1.48 (0.93–2.37) 2.67 0.10
1.18 (0.64–2.18) 0.27 0.60
13.71 (6.71–28.00) 51.55 o0.001
2.14 (1.40–3.26) 12.54 o0.001
1.42 (0.92–2.20) 2.47 0.12
0.87 (0.55–1.37) 0.39 0.53
2.41 (1.53–3.80) 14.43 o0.001
3.95 (2.36–6.60) 27.51 o0.001
variate analysis were entered (estimated duration of disease, use of antidepressants,
mood, presence of anxiety, presence of apathy, presence of irritability, presence of
the model.
d P-value by binary logistic regression.
Table 3
Predictors of suicidal ideation at follow-up in Huntington's disease mutation carriers.
Univariate Cox regression (n¼942)a
No suicidal ideation at follow-up (n¼890) Suicidal ideation at follow-up (n¼52)
Baseline variable Reference Hazard ratio (95% CI)b Wald statisticb df¼1 P-valueb
Sociodemographic characteristics
Male gender 1.00 0.91 (0.53–1.57) 0.11 0.74
Age 1.00 1.00 (0.98–1.02) 0.01 0.95
Clinical characteristics
CAG repeats 1.00 0.98 (0.92–1.05) 0.25 0.62
Estimated duration of disease 1.00 0.99 (0.96–1.03) 0.25 0.62
TFC score 1.00 0.99 (0.91–1.07) 0.10 0.76
UHDRS-motor score 1.00 1.00 (0.98–1.01) 0.08 0.78
Pre-motor symptomatic 1.00 1.78 (0.55–5.72) 0.94 0.33
Psychotropic medication
Antidepressant use 1.00 1.72 (0.98–3.02) 3.59 0.06
Antipsychotic use 1.00 1.69 (0.95–3.01) 3.16 0.08
Benzodiazepine use 1.00 2.78 (1.48–5.22) 10.14 0.001
Mood stabilizer/anti-epileptic use 1.00 2.80 (1.36–5.76) 7.85 0.005
Tetrabenazine use 1.00 2.43 (0.59–10.03) 1.50 0.22
Neuropsychiatric characteristics
Depressed mood 1.00 2.73 (1.57–4.76) 12.58 o0.001
Anxiety 1.00 1.99 (1.15–3.42) 6.11 0.01
Apathy 1.00 2.27 (1.30–3.96) 8.22 0.004
Irritability 1.00 1.48 (0.86–2.55) 1.99 0.16
Aggression 1.00 1.58 (0.85–2.92) 2.10 0.15
Suicide attempt in past 1.00 2.32 (0.92–5.84) 3.19 0.07
TFC denotes total functional capacity; UHDRS, uniﬁed Huntington's disease rating scale. 49 missing values for antidepressant use; 39 missing values for antipsychotic use; 44
missing values for benzodiazepine use; 12 missing values for mood stabilizer/anti-epileptic use; 26 missing values for tetrabenazine use; 1 missing value for presence of
anxiety; 8 missing values for presence of apathy; 5 missing values for presence of irritability; 9 missing values for presence of aggression.
a Three cases were censored before the earliest event in the stratum.
b Hazard ratio, 95% conﬁdence interval (CI), Wald statistic, degrees of freedom (df), and P-value by univariate Cox regression analysis.
Table 4
Independent predictors of suicidal ideation at follow-up in Huntington's disease mutation carriers.
Multivariate Cox regression (n¼885)a
No suicidal ideation at follow-up (n¼838) Suicidal ideation at follow-up (n¼47)
Baseline variable Reference Hazard ratio (95% CI)b Wald statisticb df¼1 P-valueb
Sociodemographic characteristics
Male gender 1.00 1.03 (0.57–1.84) 0.01 0.94
Age 1.00 1.00 (0.97–1.02) 0.12 0.73
Psychotropic medication
Benzodiazepine use 1.00 2.44 (1.20–4.97) 6.00 0.01
Mood stabilizer/anti-epileptic use 1.00 1.96 (0.88–4.35) 2.71 0.10
Neuropsychiatric characteristics
Depressed mood 1.00 2.05 (1.06–3.96) 4.50 0.03
Anxiety 1.00 0.97 (0.50–1.88) 0.01 0.93
Apathy 1.00 1.67 (0.87–3.20) 2.35 0.13
Covariates Cox regression analysis (enter model): all variables with P-value ≤0.05 in the univariate Cox regression analysis were entered (use of benzodiazepines, use of mood
stabilizers/anti-epileptics, presence of depressed mood, presence of anxiety, and presence of apathy) and sex, age, and country were forced into the model.
a Three cases were censored before the earliest event in the stratum and there were 57 cases excluded due to missing values.
b Hazard ratio, 95% conﬁdence interval (CI), Wald statistic, degrees of freedom (df), and P-value by multivariate Cox regression analysis.
A.A.M. Hubers et al. / Journal of Affective Disorders 151 (2013) 248–258252Longitudinally, a depressed mood and use of benzodiazepines at
baseline predicted suicidal ideation at follow-up.
The presence of a depressed mood was the most important
correlate and predictor of suicidal ideation. This association was
previously found among both pre-motor and motor symptomatic
HD mutation carriers (Hubers et al., 2012). Besides depressed
mood, we also found an association between the presence of
anxiety and suicidal ideation. In a previous study, the depression/
anxiety factor of the UHDRS-b was found to be a correlate ofsuicidal ideation in HD (Wetzel et al., 2011). Longitudinally, these
results were conﬁrmed as presence of depressed mood at baseline
predicted suicidal ideation at follow-up, in line with two previous
longitudinal studies, which reported depressed mood as a pre-
dictor for suicidal thoughts (Hubers et al., 2012) and attempts
(Fiedorowicz et al., 2011; Hubers et al., 2012).
Moreover, aggression and a suicide attempt in the past were
correlates of suicidal ideation. A previous multi-site study also found
aggression as a correlate of suicidal ideation in HD (Wetzel et al., 2011).
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Fig. 2. Hazard ratio (HR), 95% conﬁdence interval (CI), and P-value by univariate Cox regression analysis. Kaplan–Meier curves showing cumulative incidence of suicidal
ideation according to baseline presence of a depressed mood (Box A) and baseline benzodiazepine use (Box B).
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suicidal ideation at follow-up in our study, it was previously found as a
predictor for suicide attempts among prodromal HD mutation carriers
(Fiedorowicz et al., 2011) and it is one of the strongest risk factors for
completed suicide in the general population (Moscicki, 2001).
Although attempted suicide is a well-established risk factor for
completed suicide, it is debatable whether or not suicidal ideation
itself is a risk factor for completed suicide (Large and Nielssen, 2012).
Therefore, future studies need to investigate and describe trajectories
of suicidality in HD, and determine whether and to what extend
suicidal ideation is a clinically relevant predictor for completed suicide.
Furthermore, a shorter estimated disease duration was corre-
lated to suicidal ideation. Several authors have previously sug-
gested that completed suicide occurs more frequently in the early
stages of HD (Di Maio et al., 1993; Farrer, 1986; Lipe et al., 1993;
Schoenfeld et al., 1984). One study described two critical periods of
suicidal ideation in HD: one when at-risk persons start to
experience the ﬁrst symptoms of HD, and one when patients
become more dependent on others for daily functioning (Paulsenet al., 2005). Both critical periods are in a relatively early course of
the disease.
The use of benzodiazepines at baseline also predicted suicidal
ideation at follow-up. It is known among patients with other
disorders that use of benzodiazepines may lead to a paradoxical
reaction with behavioural disinhibition, especially in those with
impulse control problems and pre-existing neurological disorders
(Paton, 2002). Since HD mutation carriers often have difﬁculty
with impulse control already as result of disruption of frontal-
subcortical circuitry (Bonelli and Cummings, 2007; Wetzel et al.,
2011), they may indeed be at higher risk for paradoxical reactions
to benzodiazepine use. Previous studies in other populations did
not only show an association between impulsivity and suicidal
behaviour (Brenzo et al., 2006; Gvion and Apter, 2011), but also
suggested that benzodiazepine use may be associated with
attempted suicide (Neutel and Patten, 1997; Shih et al., 2013). In
our predictive study, there was no information regarding impul-
sivity and attempted and completed suicide during the study
period, and we did not investigate which participants still used
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relationship between benzodiazepine use, impulsivity, and suicid-
ality is necessary. Furthermore, the relationship between benzo-
diazepine use and suicidal ideation might be due to confounding
by indication, as benzodiazepines are prescribed mainly to
patients with symptoms of anxiety, which was a correlate of
suicidal ideation in this study, and irritability and insomnia, which
were correlates of suicidal ideation in other populations (Conner
et al., 2004; McCall et al., 2010). Also other unmeasured neurop-
sychiatric characteristics, like personality traits or coping styles,
could be the reason for both more prevalent suicidal ideation and
the use of benzodiazepines. Confounding by indication was con-
sidered the most likely explanation in a previous study that
reported an association between benzodiazepine use and suicide
attempts (Neutel and Patten, 1997).
Although there was variance in suicidal ideation prevalences
among countries, baseline suicidal ideation prevalences in the
three largest participating countries (Germany, United Kingdom,
and Poland) were around 8.0%. It is unclear whether the variance
between other countries corresponded to true differences or
whether this may be explained by measurement error (country-
speciﬁc over- and underestimation of the true prevalences), as
assessment and expression of suicidal ideation between countries
might differ depending on the cultural context and professional
traditions. Since the distribution of prevalence rates did not
correspond with the distribution of prevalence rates in the general
populations of the different European countries (Bernal et al.,
2007), our analyses focused on correlates and predictors of suicidal
ideation irrespective of the country. It is reasonable to assume that
correlates and predictors found in this study generalize to the
entire European HD population, since previous research showed
consistent risk factors in European countries despite important
variation in country prevalences (Bernal et al., 2007).
The strength of this European cohort study is the large size and
the high quality of monitored data, the use of structured electronic
case report forms, the annual training of the study site raters, and
the combination of cross-sectional and longitudinal analyses.
This study has several limitations that warrant discussion. Our
prevalence of 8.0% is much lower than a recent study that found a
prevalence of 20% (Hubers et al., 2012). However, in this study,
assessment of suicidal ideation was done by psychiatrists through
a detailed psychopathology interview (Hubers et al., 2012). A
prevalence of 19% has been found using the UHDRS-b, but this
study also categorized participants with a total score of 1 point as
suicidal (Wetzel et al., 2011). Another study using the severity
score of the ‘suicidal thoughts’ item of the UHDRS-b to assess
participants for suicidal ideation reported a prevalence of 17.5%
(Paulsen et al., 2005). However, when all mildly suicidal partici-
pants (severity score of 1) were excluded, the prevalence dropped
to 10.3% (Paulsen et al., 2005), which is much more in accordance
with the prevalence found in our study. Although the suicidal
ideation prevalence found in our study is lower than reported in
previous studies, a suicidal ideation one-month prevalence of 8.0%
among HD mutation carriers is still much higher compared with
the one-month prevalence of 0.0% recently found among non-HD
controls (Hubers et al., 2012) and the twelve-month prevalence of
2.0% in the general population (Borges et al., 2010). The lower
prevalence found in our study compared with previous HD studies
may be explained by the design of REGISTRY, which measured a lot
of motor and cognitive symptoms, while the assessment of
neuropsychiatric symptoms is rather sparse. A detailed and
extensive psychopathology interview is probably more sensitive
to detect suicidal ideation in HD, as was previously recommended
by the authors of a multi-site HD study (Wetzel et al., 2011).
Additionally, psychiatrists may be better trained than neurologists
in detecting subtle suicidal thoughts, as assessing suicidality is animportant part of their psychiatric training. Furthermore, a selec-
tion of HD mutation carriers who were stable enough at the time
of enrolment and subsequent follow-up visits participated in this
study. HD patients attending REGISTRY clinics might be less
disturbed and better treated; and, there was a substantial number
of drop-outs, which may have caused attrition bias. This may have
resulted in limited generalizability of the prevalence and incidence
found in this study, as it probably is an underestimation of the
prevalence and incidence in the general HD population. Another
important limitation of this study is that only one item of the
UDHRS-b was used to assess suicidal ideation. Finally, only pre-
dictors of suicidal ideation could emerge from this observational
study and we cannot conclude whether these are causal
relationships.
Because of the high prevalence of suicidal ideation in HD, it is
important to regularly screen mutation carriers for the presence of
suicidal ideation. In depressed HD mutation carriers assessment of
suicidal ideation is a priority, especially since depressed mood is a
potential treatable risk factor. Furthermore, clinicians should be
aware when mutation carriers are using benzodiazepines, since
use of benzodiazepines predicted suicidal ideation at follow-up.Role of funding source
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